相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha
Dushyant Verma et al.
LEUKEMIA & LYMPHOMA (2008)
How I treat chronic myeloid leukemia in the imatinib era
John M. Goldman
BLOOD (2007)
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot et al.
BLOOD (2007)
Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph plus CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon
M. Breccia et al.
LEUKEMIA RESEARCH (2006)
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α
HM Kantarjian et al.
BLOOD (2004)
To the editor: Discontinuation of imatinib therapy after achieving a molecular response
J Cortes et al.
BLOOD (2004)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
分享论文
